Clinical Trial Update: Open Label Study for the Evaluation of Tolerability of Five Dose Levels of Cand5 [Phase 1]

View source ↗

Summary

An open-label Phase 1 study evaluating tolerability across five dose levels of Cand5 in macular degeneration, with the study now completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• Cand5 (Cand5 siRNA)

Snippet

Sponsor: OPKO Health, Inc. | Conditions: Macular Degeneration | Phase 1 | Status: COMPLETED